Autres langues Kezar Life Sciences, Inc.

Actions

KZR

US49372L1008

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,8574 ^USD	+0,32 %		+6,52 %	-9,50 %

14/03	Kezar Life Sciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
14/03	Kezar Life Sciences, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	08/04
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update	14/03
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	08/03
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis	27/02
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from NASDAQ Biotechnology Index	15/12
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)	04/12
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	21/11
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update	13/11
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	09/11
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	03/11
KEZAR ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)	10/10/23
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	10/10/23
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	09/10/23
North American Morning Briefing : Investors Await -2-	06/10/23
Kezar Life Sciences Launches Restructuring Program, Cuts Workforce, Names New CEO	03/10/23
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer	03/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kezar Life Sciences, Inc.

Actions

KZR

US49372L1008

Autres langues

Filtres